TL;DR
The MHRA, the UK’s medicines and devices regulator, published its strategy to 2030 on Wednesday 14 October, and AI runs through it: a new “Centre for AI and Digital Health”, an action plan on AI in medicines development due in 2027, an “adaptive” framework for AI used as a medical device, and AI deployed inside the agency to check trial protocols and hunt for safety signals in real-world data. Chief executive Lawrence Tallon says AI is changing “both regulated products and how organisations are run”, and the strategy treats it as both. For UK developers, the operational promises are as concrete as the AI ones: scientific advice in 45 days rather than 90, and a 14-day first assessment for qualifying Phase 1 trials.
The AI commitments
Four items sit under the heading of transforming regulation with AI. An AI-enabled protocol checker for clinical trials is meant to give sponsors certainty before they submit. The 2027 action plan will set out how AI is used across the development of medicines. The new centre is intended to make expectations clearer for developers of AI-driven devices and medicines. And the agency commits to a modern, adaptive framework for AI-based medical devices. Separately, under real-world evidence, it plans to recruit specialist skills and apply AI to hospital and genomics data to spot safety issues earlier, alongside the Health Data Research Service on real-time surveillance.
EMJ’s preview of the document, published before release, adds the mechanics: continuous monitoring of AI devices whose performance drifts across settings and populations, “expanded predetermined change control plans” for pre-agreed model updates, and proposed master files so developers can share safety data on the foundation models underneath.
Beyond AI
The strategy also cuts the target for first assessment of qualifying Phase 1 trials by half, to 14 days, offers a paid fast track that brings scientific advice down from 90 to 45 days, and sets a voucher scheme to ease regulation for UK start-ups. On enforcement, it pledges more criminal capacity against illegal medicines and engagement with social platforms and online marketplaces on misinformation.
Health innovation minister James Frith said the strategy would help the MHRA “keep pace with the latest innovations in AI, data and medicine”.
Why it matters
The MHRA is the regulator UK health-tech firms meet first, and the document follows the government’s response to the National Commission on AI regulation in healthcare earlier this month. In our view the test of the new centre will be whether it shortens the path for the smaller developers the voucher scheme targets, or becomes another body those developers must satisfy.
Looking forward
Dates to watch are the 2027 action plan and the “this year” commitments on a Women’s Health Plan and patient involvement. EMJ’s preview says statutory sandboxes depend on legislative reform, so the adaptive device framework is likely to arrive in stages rather than at once.